40 results
8-K
EX-99.1
APTX
Aptinyx Inc.
30 Mar 23
Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives
4:15pm
and expenses, and the effect of the COVID-19 pandemic on the foregoing. Risks that contribute to the uncertain nature of the forward-looking statements include … : the effect of the COVID-19 pandemic on our business and financial results, including with respect to disruptions to our clinical trials, business
8-K
EX-99.1
APTX
Aptinyx Inc.
8 Nov 22
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
4:15pm
nature of the forward-looking statements include: the effect of the COVID-19 pandemic on the company’s business and financial results, including
8-K
EX-99.1
APTX
Aptinyx Inc.
12 Aug 22
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia
7:15am
pandemic on our business and financial results, including with respect to disruptions to our clinical trials, business operations, and ability to raise
8-K
EX-99.1
bdcxni
4 Aug 22
Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights
4:15pm
8-K
EX-99.1
ar01joqswxvw 5g2fu
12 May 22
Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress
4:16pm
8-K
EX-99.1
clhe4jvttb
7 Apr 22
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
7:15am
424B5
pfk9fauc
31 Mar 22
Prospectus supplement for primary offering
4:45pm
8-K
EX-99.1
y4i 4ueaj0rd4e9vxux2
23 Mar 22
Aptinyx Reports Fourth Quarter and Full Year 2021 Results and Highlights
4:05pm
8-K
EX-99.1
d31zqvs8wb u9
9 Feb 22
Regulation FD Disclosure
12:00am
8-K
EX-99.1
nyc5xd
9 Nov 21
Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights
4:17pm
8-K
EX-99.1
y16zxtrbidzi4f4snmw
27 Oct 21
Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic
7:16am
424B5
0fqgezqkiwt8z8u7kjk
16 Sep 21
Prospectus supplement for primary offering
7:47am